|
|
???tair.name??? >
???browser.page.title.author???
|
"llovet j m"???jsp.browse.items-by-author.description???
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2021-08-31T06:29:40Z |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Milestones in the pathogenesis and management of primary liver cancer
|
Nault J.-C.; ANN-LII CHENG; Sangro B.; Llovet J.M. |
| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu A.X.;Finn R.S.;Kang Y.-K.;Yen C.-J.;Galle P.R.;Llovet J.M.;Assenat E.;Brandi G.;Motomura K.;Ohno I.;Daniele B.;Vogel A.;Yamashita T.;Chih-Hung Hsu;Gerken G.;Bilbruck J.;Hsu Y.;Liang K.;Widau R.C.;Wang C.;Abada P.;Kudo M.; Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu A.X.;Finn R.S.;Kang Y.-K.;Yen C.-J.;Galle P.R.;Llovet J.M.;Assenat E.;Brandi G.;Motomura K.;Ohno I.;Daniele B.;Vogel A.;Yamashita T.;Chih-Hung Hsu;Gerken G.;Bilbruck J.;Hsu Y.;Liang K.;Widau R.C.;Wang C.;Abada P.;Kudo M.; Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: Pooled results from two phase 3 studies (REACH and REACH-2)
|
Kudo, M.;Finn, R.S.;Morimoto, Morimoto M.;Rau, K.-M.;Ikeda, M.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Daniele, B.;Lim, H.Y.;McIlwain, D.W.;Yoshikawa, R.;Nakamura, K.;Liang, K.;Wang, C.;Abada, P.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu, A.X.;Finn, R.S.;Kang, Y.-K.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Motomura, K.;Ohno, I.;Daniele, B.;Vogel, A.;Yamashita, T.;Hsu, C.-H.;Gerken, Gerken G.;Bilbruck, J.;Hsu, Y.;Liang, K.;Widau, R.C.;Wang, C.;Abada, P.;Kudo, M. |
| 國立成功大學 |
2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, A.X.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Pracht, M.;Lim, H.Y.;Rau, K.-M.;Motomura, K.;Ohno, I.;Merle, P.;Daniele, B.;Shin, D.B.;Gerken, Gerken G.;Borg, C.;Hiriart, J.-B.;Okusaka, T.;Morimoto, Morimoto M.;Hsu, Y.;Abada, P.B.;Kudo, M.;investigators, REACH-2 study |
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
